Simulations probe the role of space in the interplay between drug-sensitive and drug-resistant cancer cells

Author:

Pugh Kira,Jones Rhys DO,Powathil Gibin,Hamis Sara

Abstract

AbstractThe interplay between drug-sensitive and drug-resistant cancer cells has been observed to impact cell-to-cell interactions in experimental settings. However, the role that space plays in these interactions remains unclear. In this study, we develop mathematical models to investigate how spatial factors affect cell-to-cell competition between drug-sensitive and drug-resistant cancer cells in silico. We develop two baseline models to study cells from the epithelial FaDu cell line subjected to two drugs, specifically the ATR inhibitor ceralasertib and the PARP inhibitor olaparib, that target DNA damage response pathways. Our baseline models are: (1) a temporally resolved ordinary differential equation (ODE) model, and (2) a spatio-temporally resolved agent-based model (ABM). The models simulate cells in well-mixed and spatially structured cell systems, respectively. The ODE model is calibrated against in vitro data and is thereafter mapped onto the baseline ABM which, in turn, is extended to enable a simulation-based investigation on how spatial factors impact cell-to-cell competition. Simulation results from the extended ABMs demonstrate that the in silico treatment responses are simultaneously affected by: (i) the initial spatial cell configurations, (ii) the initial fraction of drug-resistant cells, (iii) the drugs to which cells express resistance, (iv) drug combinations, (v) drug doses, and (vi) the doubling time of drug-resistant cells compared to the doubling time of drug-sensitive cells. These results reveal that spatial structures of the simulated cancer cells affect both cell-to-cell interactions, and the impact that these interactions have on the ensuing population dynamics. This leads us to suggest that the role that space plays in cell-to-cell interactions should be further investigated and quantified in experimental settings.

Publisher

Cold Spring Harbor Laboratory

Reference56 articles.

1. R. Aggarwal . Ceralasertib (AZD6738) alone and in combination with olaparib or durvalumab in patients with solid tumors. Identifier NCT03682289 , 2019. URL https://clinicaltrials.gov/study/NCT03682289?cond=ceralasertib%20and%20olaparib&rank=2#study-plan.

2. Factors and molecular mechanisms of radiation resistance in cancer cells

3. Spartan: A Comprehensive Tool for Understanding Uncertainty in Simulations of Biological Systems

4. Deciphering cell–cell interactions and communication from gene expression

5. AstraZeneca. A study of ceralasertib monotherapy and ceralasertib plus durvalumab in patients with melanoma and resistance to PD-(L)1 inhibition (monette). Identifier NCT05061134 , 2022a. URL https://clinicaltrials.gov/study/NCT05061134?cond=NCT05061134&rank=1.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3